Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBP{beta}-deficient hematopoietic cells.

Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBP{beta}-deficient hematopoietic cells. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBP{beta}-deficient hematopoietic cells. Abstract Text:

Transcription factors known as CCAAT enhancer binding proteins (C/EBPs) are involved in hematopoietic differentiation, including myelopoiesis and granulopoiesis. C/EBPbeta-deficient mice develop normally; however, they exhibit defective macrophage function, resulting in increased susceptibility to infection. Little is known about the role of C/EBPbeta in granulopoiesis; therefore, we examined granulopoiesis in C/EBPbeta-deficient mice. Morphology, the number of peripheral blood and bone marrow cells, and the expression of genes specific for the myeloid lineage were normal in C/EBPbeta-deficient mice. Interestingly, the hematopoietic progenitor cells of C/EBPbeta-deficient mice did not respond normally to granulocyte/macrophage-colony stimulating factor and granulocyte colony stimulating factor. In addition, C/EBPbeta-deficient neutrophils displayed enhanced apoptosis compared with wild-type neutrophils. Our present results indicate that C/EBPbeta helps regulate survival of neutrophils, downstream of the granulocyte colony stimulating factor receptor.

Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBP{beta}-deficient hematopoietic cells. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBP{beta}-deficient hematopoietic cells. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Blood

VOLUME: 111

Page Numbers: 2999-3004

Journal Abbreviation: Blood

ISSN: 0006-4971

DAY: 4

MONTH: 12

YEAR: 2007

Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBP{beta}-deficient hematopoietic cells. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7603509

Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBP{beta}-deficient hematopoietic cells. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBP{beta}-deficient hematopoietic cells. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBP{beta}-deficient hematopoietic cells.

AFFILIATION:

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Blood

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBP{beta}-deficient hematopoietic cells Related Publications

• 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
• A Role for the PPARgamma in Cancer Therapy.
• ATF4 differentially regulates transcriptional activation of myeloid-specific genes by C/EBPepsilon and C/EBPalpha.
• Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders.
• Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy.
• CYR61: a new measure of lung cancer outcome.
• Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray.
• Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells.
• Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme.
• Functional domains of CCN1 (Cyr61) regulate breast cancer progression.
• Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin.
• Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
• Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
• Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBP{beta}-deficient hematopoietic cells.
• In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies.
• KLF6: mutational analysis and effect on cancer cell proliferation.
• Modulation of DNA binding properties of CCAAT/enhancer binding protein epsilon by heterodimer formation and interactions with NFkappaB pathway.
• Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia.
• Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray.
• PC-SPES down-regulates COX-2 via inhibition of NF-kappaB and C/EBPbeta in non-small cell lung cancer cells.
• Quantum dot labeling and tracking of human leukemic, bone marrow and cord blood cells.
• RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation.
• Regulation of the CAMP gene by 1,25(OH)2D3 in various tissues.
• SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
• The clock gene Per2 links the circadian system to the estrogen receptor.
• The role of circadian regulation in cancer.
• Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer.
• Vitamin D analogs and breast cancer.
• Vitamin D compounds and myelodysplastic syndrome.
• [On the pathogenesis, clinical aspects and differential diagnosis of symptomatic aplastic forms of anemia with a final picture of leukosis.]